These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 15631536)

  • 1. Therapeutic potential of rho-kinase inhibitors in cardiovascular diseases.
    Hirooka Y; Shimokawa H
    Am J Cardiovasc Drugs; 2005; 5(1):31-9. PubMed ID: 15631536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rho-kinase is an important therapeutic target in cardiovascular medicine.
    Shimokawa H; Takeshita A
    Arterioscler Thromb Vasc Biol; 2005 Sep; 25(9):1767-75. PubMed ID: 16002741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Rho and Rho-kinase in the treatment of cardiovascular disease.
    Budzyn K; Marley PD; Sobey CG
    Trends Pharmacol Sci; 2006 Feb; 27(2):97-104. PubMed ID: 16376997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ROCKs as therapeutic targets in cardiovascular diseases.
    Rikitake Y; Liao JK
    Expert Rev Cardiovasc Ther; 2005 May; 3(3):441-51. PubMed ID: 15889972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rho-kinase: important new therapeutic target in cardiovascular diseases.
    Satoh K; Fukumoto Y; Shimokawa H
    Am J Physiol Heart Circ Physiol; 2011 Aug; 301(2):H287-96. PubMed ID: 21622831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progress of the study of rho-kinase and future perspective of the inhibitor.
    Tawara S; Shimokawa H
    Yakugaku Zasshi; 2007 Mar; 127(3):501-14. PubMed ID: 17329936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-ischemic effects of fasudil, a specific Rho-kinase inhibitor, in patients with stable effort angina.
    Fukumoto Y; Mohri M; Inokuchi K; Ito A; Hirakawa Y; Masumoto A; Hirooka Y; Takeshita A; Shimokawa H
    J Cardiovasc Pharmacol; 2007 Mar; 49(3):117-21. PubMed ID: 17414222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cardiovascular protective action of Rho-kinase inhibitors].
    Hirooka Y
    Nihon Rinsho; 2004 Jan; 62(1):161-71. PubMed ID: 14737849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rho-kinase inhibition in the therapy of cardiovascular disease.
    Lai A; Frishman WH
    Cardiol Rev; 2005; 13(6):285-92. PubMed ID: 16230885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rho-kinase as a novel therapeutic target in treatment of cardiovascular diseases.
    Shimokawa H
    J Cardiovasc Pharmacol; 2002 Mar; 39(3):319-27. PubMed ID: 11862109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rho-kinase inhibition with intracoronary fasudil prevents myocardial ischemia in patients with coronary microvascular spasm.
    Mohri M; Shimokawa H; Hirakawa Y; Masumoto A; Takeshita A
    J Am Coll Cardiol; 2003 Jan; 41(1):15-9. PubMed ID: 12570938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2015 ATVB Plenary Lecture: translational research on rho-kinase in cardiovascular medicine.
    Shimokawa H; Satoh K
    Arterioscler Thromb Vasc Biol; 2015 Aug; 35(8):1756-69. PubMed ID: 26069233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vasodilatory effect of subsequent administration of fasudil, a rho-kinase inhibitor, surpasses that of nitroglycerin at the concentric coronary stenosis in patients with stable angina pectoris.
    Otsuka T; Ibuki C; Suzuki T; Ishii K; Kodani E; Atarashi H; Kishida H; Takano T
    Circ J; 2006 Apr; 70(4):402-8. PubMed ID: 16565555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of Rho-kinase by fasudil attenuated angiotensin II-induced cardiac hypertrophy in apolipoprotein E deficient mice.
    Wang YX; da Cunha V; Martin-McNulty B; Vincelette J; Li W; Choy DF; Halks-Miller M; Mahmoudi M; Schroeder M; Johns A; Light DR; Dole WP
    Eur J Pharmacol; 2005 Apr; 512(2-3):215-22. PubMed ID: 15840407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rho-kinase, a potential therapeutic target for the treatment of hypertension.
    Hirooka Y; Shimokawa H; Takeshita A
    Drug News Perspect; 2004 Oct; 17(8):523-7. PubMed ID: 15605112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Involvement of small GTPase Rho and Rho-kinase in the pathogenesis of hypertension and hypertensive target organ damage].
    Nakayama M; Amano M; Kawabata S; Kaibuchi K; Takefuji M
    Nihon Rinsho; 2004 Mar; 62 Suppl 3():202-6. PubMed ID: 15171369
    [No Abstract]   [Full Text] [Related]  

  • 17. Rho-kinase as a potential therapeutic target for the treatment of pulmonary hypertension.
    Xing XQ; Gan Y; Wu SJ; Chen P; Zhou R; Xiang XD
    Drug News Perspect; 2006 Nov; 19(9):517-22. PubMed ID: 17220956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-anginal effect of fasudil, a Rho-kinase inhibitor, in patients with stable effort angina: a multicenter study.
    Shimokawa H; Hiramori K; Iinuma H; Hosoda S; Kishida H; Osada H; Katagiri T; Yamauchi K; Yui Y; Minamino T; Nakashima M; Kato K
    J Cardiovasc Pharmacol; 2002 Nov; 40(5):751-61. PubMed ID: 12409984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Central Angiotensin-II Increases Blood Pressure and Sympathetic Outflow via Rho Kinase Activation in Conscious Rabbits.
    Pellegrino PR; Schiller AM; Haack KK; Zucker IH
    Hypertension; 2016 Nov; 68(5):1271-1280. PubMed ID: 27672026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats.
    Abe K; Shimokawa H; Morikawa K; Uwatoku T; Oi K; Matsumoto Y; Hattori T; Nakashima Y; Kaibuchi K; Sueishi K; Takeshit A
    Circ Res; 2004 Feb; 94(3):385-93. PubMed ID: 14670839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.